With nearly 35 years of experience in health economics and outcomes research, and consulting for the healthcare industry, Mr. Tierce is a pioneer in the field of applied pharmacoeconomics, pharmacoepidemiology, and value demonstration.
Mr. Tierce is well known for providing innovative and yet practical strategies for evidence development – based on an in-depth understanding of market forces and decision-maker imperatives – for a range of clients from the public and private healthcare sectors.
With many years in the industry, as a founding leader of several HEOR business units, the path breaking ValueMedics Research, Inc., and a 3-year tenure as General Manager, Global Health Economics and Outcomes Research at IMS Consulting. Mr. Tierce has worked for dozens of clients and on hundreds of medical technologies.
He was advanced to candidacy for a Ph.D. in political science and received post-graduate training in econometrics and experimental design at the University of California, Los Angeles, where he also earned his B.A. cum laude and Masters of Arts.
Francine Chingcuanco’s background is in epidemiology and pharmacology. Prior to joining Monument, she consulted for the Health Outcomes Research Department of Millennium Health wherein she designed and managed clinical research studies aimed at developing real-world evidence to support products in the field of personalized medicine. She received her Masters in Health Science from Johns Hopkins Bloomberg School of Public Health as well as an Honours Bachelor of Science from the University of Toronto.
Benjamin Cohen specializes in health economics and outcomes research. He received his PhD from the University of Southern California School of Pharmacy where he evaluated the costs and benefits of spending in chronic diseases using administrative claims, microsimulations, and survey data. Prior to starting his doctorate program, he received a Masters in Public Health from Columbia University Mailman School of Public Health. He has previous experience working in the pharmaceutical and biotechnology industry.
Cullen Conway, MPH, specializes in research and interventions surrounding the social determinants of health. Prior to joining Monument Analytics, Cullen managed projects focused on screening community members for health-related social needs associated with the social determinants of health – working to connect individuals with identified needs to resources in their communities, ultimately focused on moving upstream to proactive disease prevention rather than reactive treatment. Cullen received a Masters in Public Health from Columbia University Mailman School of Public Health.
Karen Dietz, MHS, Manager, specializes in complex project management, outcomes research, and vaccines. Previously, she worked as a management consultant with enterprise clients across a variety of sectors, including life sciences and pharmaceutical industries. Karen has experience managing multiple outcomes-based research programs and clinical trials at the Johns Hopkins School of Medicine. Karen received her Master of Health Science from Johns Hopkins Bloomberg School of Public Health, with a Certificate in Vaccine Science and Policy, and a Bachelor of Science from Virginia Tech.
Elena Fernandez specializes in pharmacoeconomics and health outcomes. She received her PhD from the Department of Pharmacotherapy and Outcomes Sciences at Virginia Commonwealth University, where she designed and conducted research applying econometric models to evaluate opioid utilization in cancer survivors. Prior to her graduate training, she worked as a cancer research training award (CRTA) fellow at the National Cancer Institute. She also received a Doctor of Pharmacy from Virginia Commonwealth University and a Bachelor of Science in biochemistry from the University of Mary Washington.
Katharine Ozenberger specializes in epidemiology and pharmacoepidemiology. She is a PhD candidate in the Department of Pharmacy Systems, Outcomes, and Policy at the University of Illinois at Chicago where she designs and conducts research using longitudinal data from population-based cohorts, prescription dispensing, and commercial insurance claims. She received her Masters in Science in epidemiology from the University of Illinois at Chicago’s School of Public Health and a Bachelor of Science in biology from the University of Colorado Denver.
Eileen Rosello, Senior Analyst, specializes in clinical research and project management. Prior to joining Monument Analytics, she worked as a research program coordinator inthe setting of academia at Johns Hopkins School of Medicine and private enterprise. Eileen has experience managing end-to-end operations for an expansive array of clinical protocols in oncology, transplant epidemiology, and behavioral pharmacology. She received her Bachelor of Arts in Natural Sciences from Johns Hopkins University and has completed graduate coursework in Molecular and Cellular Biology at Johns Hopkins Bloomberg School of Public Health.
Rachel Nadboy supports Monument’s work as an analyst through epidemiological research, analysis, and providing support to team members across multiple work streams including litigation. She received a Bachelor of Arts in History and Science from Harvard College, where she researched the history of occupational health for her senior thesis and was interested in the interaction between the social sciences and the life sciences.
Paul Steel, MHS, Analyst, supports Monument through research and analysis, literature reviews, and project management across various work streams. Paul received a Master of Health Science in Environmental Health and Engineering from the Johns Hopkins School of Public Health, where he conducted a systematic literature review for his thesis on the alleged toxicity of synthetic turf fields. Paul also holds a Bachelor of Arts in Medicine, Science and the Humanities from Johns Hopkins University, while he tenured as a four-year varsity lacrosse player.
Danyang Wang specializes in economic modeling and cost-effectiveness analysis. Before joining Monument Analytics she developed probabilistic Markov models to assess the cost-effectiveness of community health interventions while in training at Johns Hopkins Bloomberg School of Public Health. She received her Master of Health Science from Johns Hopkins Bloomberg School of Public Health and a Bachelor of Science in Biology with a minor in Economics from Emory University.
Ellen Hu specializes in economic evaluation and has background in healthcare actuarial modeling. Prior to joining Monument, she worked in actuarial consulting where she performed valuations and projections for public and private employer sponsored retiree health plans as well as performed health plan rate settings and design modeling. She received her Master of Health Science from Johns Hopkins Bloomberg School of Public Health and a Bachelor of Arts in Economics with a minor in Mathematics from DePauw University.
Divya Mohan’s background is in health economics and biomedical engineering. She specializes in patient preferences and cost-effectiveness analysis. Previously she worked at the Economist Intelligence Unit on projects including concept testing, communications strategy, market sizing, as well as customer perception and insight studies for imaging systems, in-vitro diagnostics, surgical devices, and procedures. She received her Masters in Health Science from Johns Hopkins Bloomberg School of Public Health and a Bachelor of Engineering from Nanyang Technological University.
Jeromie Ballreich is an Assistant Scientist and Director of the Master of Health Sciences in Health Economics program in the Department of Health Policy and Management at Johns Hopkins Bloomberg School of Public Health. He received his Ph.D. in Health Economics from Johns Hopkins Bloomberg School of Public Health with a thesis in “Price Discrimination in the US Cancer Drug Market.” Previously, Dr. Ballreich received his Master in Health Economics also from JHSPH and a Bachelors in Mathematics and Economics from Lafayette College.
Dr. Hazard has over twenty years of experience working as a health care consultant. She was a founding leader of Value Medics Research, Inc. Her specialty is value development and value communications. She was an early pioneer in creating value development plans for medical technologies and facilitated the understanding of how demonstrations of economic value could be used effectively by product development and marketing teams. Dr. Hazard has worked with major pharmaceutical companies in the U.S. and Europe and on dozens of medical technologies
Daniel Touchette is Professor and Director of Graduate Studies for the Masters in Comparative Effectiveness Research program at the University of Illinois at Chicago’s College of Pharmacy. His primary research interests are evaluating the cost-effectiveness of pharmaceutical agents assessing the effectiveness and cost-effectiveness of clinical pharmacist and other health practitioner services, and developing and assessing methods for improving adherence to medication regimens. Dr. Touchette has obtained grant funding from AHRQ, NIH, and numerous foundations and other sources. Most recently, he has developed decision models for the Institute for Clinical and Economic Review (ICER) and leads UIC’s involvement in ICERs Health Economic Network. He has authored over 70 peer-reviewed manuscripts and reports.
Dr. Brett McQueen is currently a tenure-track Assistant Professor at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences and a member in the Center for Pharmaceutical Outcomes Research (CePOR). His research interests include comparative effectiveness research, cost-effectiveness applications and methods development, value-based outcomes contracting, and patient preferences research. He’s active in health economics-related societies such as the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) through contributions to ISPOR short courses, workshops, issue panels, and research presentations. Dr. McQueen has led or collaborated on modeling submissions for various health technology assessment groups since 2016. He has authored over 50 publications in journals such as PharmacoEconomics, Diabetes Care, and Medical Care.
Adrian R. Levy PhD is Professor in the Department of Epidemiology and Community Health at Dalhousie University. He is author of over 150 peer reviewed publications and is the co-editor of two volumes in the Springer Handbook of Health Services Research entitled “Comparative Effectiveness Research” and “Health Services Evaluation”. His academic interests lie in health services research, health technology assessment, pharmacoepidemiology, pharmacoeconomics, quality of life, and access to care.
Mark Sculpher is Professor of Health Economics at the Centre for Health Economics, University of York, UK where he leads the Centre’s Programme on Economic Evaluation and Health Technology Assessment. He is also Co-Director of the Policy Research Unit in Economic Evaluation of Health and Care Interventions, a programme of research for the UK Department of Health and Social Care funded by the National Institute for Health Research (NIHR).
Mark has worked in the field of economic evaluation and health technology assessment for over 30 years. He has researched in a range of clinical areas including heart disease, cancer, diagnostics, and public health. He has also contributed to research methods in the field, in particular relating to decision analytic modelling and techniques to handle uncertainty, heterogeneity and generalisability. He is also experienced in economic analysis in low income settings and is principle investigator of the Thanzi la Onse (Health for All) programme in Malawi funded by UK Research and Innovation. He has over 270 peer-reviewed publications and is a co-author of two major text books in the area: Methods for the Economic Evaluation of Health Care Programmes (OUP, 2015 with Drummond, Claxton, Torrance and Stoddart) and Decision Modelling for Health Economic Evaluation (OUP, 2006 with Briggs and Claxton).
Mark is an emeritus member of the UK NIHR College of Senior Investigators. Hehas also been a member of the National Institute for Health and Clinical Excellence (NICE) Technology Appraisal Committee and the NICE Public Health Interventions Advisory Committee. He currently sits on NICE’s Diagnostics Advisory Committee. He chaired NICE’s 2004 Task Group on methods guidance for economic evaluation and advised the Methods Working Party for the 2008 update of this guidance. Mark has advised the UK House of Commons Health and Social Care Select Committee, as well as health systems internationally on health technology assessment methods including those in France, Ireland, Japan, Singapore, Germany, Portugal, Taiwan and New Zealand. He has been a member of the Commissioning Board for the UK NHS Health Technology Assessment Programme, the UK NIHR /Medical Research Council’s Methodology Research Panel and the UK Department of Health’s Policy Research Programme’s Commissioning Panel. He served as President of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (2011-12).
Rob is currently the President of R2 Medical Solutions. Rob advises small- to mid-size domestic and international companies in the biotechnology, pharmaceutical, and medical device sectors on strategy and commercial execution in the US.
With more than two decades of experience, Rob has driven multi-million-dollar revenue growth for market leading companies in Oncology, Wound Care, Pressure Injury Prevention, and Infection Control. As President, US at Molnlycke Health Care, Rob differentiated their product solutions with clinical and health economics outcomes data.
Since 2014, Rob has been on the board of Debra of America and currently serves as the Chief Development Officer (CDO) and Chief Operating Officer (COO). Debra of America is dedicated to improving the quality of life of all people living with Epidermolysis Bullosa (EB) by providing free programs and services and funding innovative research.
Rob received an Executive MBA in Leadership from the University of Georgia, Terry College of Business, a BS in Marketing Management from Valparaiso University, and a Certificate in Leadership from the University of Virginia Darden School of Business.